Study protocol for a prospective, double-blinded, observational study investigating the diagnostic accuracy of an app-based diagnostic health care application in an emergency room setting: the eRadaR trial응급실 환경에서 앱 기반 진단 건강 관리 애플리케이션의 진단 정확도를 조사하는 전향적 이중 맹검 관찰 연구를 위한 연구 프로토콜: eRadaR 시험Article Published on 2021-01-082022-09-11 Journal: BMJ Open [Category] 임상, [키워드] abdominal pain ACCIDENT & Accuracy Admission adult gastroenterology adult surgery. artificial attending physicians blinded Care classical Clinical data Complication complications consent form Contact Decision making decision support system defined diagnose diagnoses Diagnosis diagnostic Diagnostic accuracy diagnostic decision differential diagnose differential diagnoses discharge double-blinded double-blinded study Efficacy emergency medicine emergency room ENhance Ethical approval Ethics evaluate Final Follow-up Frankfurt Health Hospital stay IEC independent information informed consent form initial Interaction International knowledge knowledge base National Occurrence outcome overall survival Patient Patient care patient information patients peer-reviewed performed Physicians presenting protocol protocol amendment registration number reported Secondary objective Secondary objectives submitted suggested Support Support System survival the patient therapy Throughout the study Trial [DOI] 10.1136/bmjopen-2020-041396 PMC 바로가기 [Article Type] Article
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical TrialCOVID-19 및 중등도 또는 중증 폐렴으로 입원한 성인에서 Tocilizumab 대 일반 치료의 효과: 무작위 임상 시험Randomized Controlled Trial Published on 2021-01-012022-09-11 Journal: JAMA Internal Medicine [Category] 임상, 진단, 치료제, [키워드] 95% CI adjusted Admission adverse event adverse events age Analysis antibiotic Anticoagulants Antiviral agents ARD assigned Bayesian C-reactive protein Care clinical clinical status clinical trial clinically conducted Consent coronavirus disease Coronavirus disease 2019 Corticosteroids COVID-19 COVID-19 pneumonia credible interval CrI death determine did not reduce died discharge Effect Efficacy elevated Factor Fewer patients Follow-up France greater hazard ratio Health Organization hyperinflammation Identifier IMPROVE indicated intensive care intensive care unit intention-to-treat basis interleukin-6 interquartile range intravenously investigator-initiated less mechanical ventilation median moderate moderate-to-severe COVID-19 pneumonia Mortality multicenter multiplicity NIV no difference Noninvasive ventilation occurred Open-label outcome overall survival oxygen oxygen supply oxygen support Patient patients patients hospitalized patients with COVID-19 performed Pneumonia posterior probability Primary outcomes randomized clinical trial Randomly receive recruited reduced risk risk difference scale secondary Secondary outcomes Serious Adverse Events severe pneumonia survival TCZ threshold Tocilizumab treat university hospital usual care usual care alone vasopressor support Ventilation WHO-CPS women World Health Organization [DOI] 10.1001/jamainternmed.2020.6820 PMC 바로가기 [Article Type] Randomized Controlled Trial
Prior surveillance and antiviral treatment improve the prognosis of HCC developed in HBV patients in the WestArticle Published on 2021-01-012023-06-12 Journal: Clinics and research in hepatology and gastroenter [Category] B형 간염, [키워드] hepatitis B infection Hepatocellular carcinoma overall survival Prognostic factors [DOI] 10.1016/j.clinre.2020.03.030
Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation조혈모세포 이식 환자에서 코로나19의 유리한 결과Clinical Trial Published on 2020-12-012022-09-12 Journal: The Journal of Clinical Investigation [Category] MERS, SARS, 임상, 진단, [키워드] active malignancy Allogeneic Antibody Response antiviral response autologous CAR Cell cell transplantation cellular center Characteristics chimeric antigen receptor clinical Clinical outcome clinical variable composite endpoint COVID-19 Critical death diagnosed disease event identify immune investigated IQR lymphocyte Lymphocyte subsets median time Memorial nasopharyngeal swabs neutropenia number of comorbidity outcome overall survival Oxygen requirement Patient patients patients with COVID-19 patients with SARS-CoV-2 Population quantitative real-time PCR recipient recipients reduction SARS-CoV-2 SARS-CoV-2 antibody severity significantly stem cell Stem cell transplantation subset T cell T cells therapy transplantation variable with COVID-19 [DOI] 10.1172/JCI141777 PMC 바로가기 [Article Type] Clinical Trial
A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trialLetter Published on 2020-10-062022-10-29 Journal: Trials [Category] COVID-19, MERS, SARS, [키워드] 1:1 active cancer addition administration age ambient analysed anti-SARS-CoV-2 Antibody titer antibody titres anticipated ARMS assessment baseline Blinding Block randomisation breathing ambient air case report form changes in Chemotherapy clearance clinical clinical condition Clinical outcome collected Confirmed Contact convalescence convalescent plasma COVID-19 criteria cross cytokine profile D-dimer death defined described diagnostic discharge discharged patient dissemination Donor Duration early application eCRF Effect element eligibility eligible eligible patient Enrollment EudraCT exclusion criteria expected experimental arm exploratory feature Follow-up follow-up period group Hematological malignancy high risk high-risk patient high-risk patients with severe disease hospital Hospital admission Hospital stay Hospitalized Immunosuppression inclusion criteria Infection infusion investigator laboratory data Last less mechanical ventilation multicenter non-parametric test number objective Open-label outcome overall survival participant Patient performed plasma positive protocol quarter Radiotherapy randomisation randomised randomised controlled trial randomization system Randomized receive recruitment Registered report reported required Requirement risk routine care Sample size SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2 disease SARS-COV-2 infection SARS-CoV-2 viral schedule secondary Secondary objective Seven seven-point ordinal scale Standard Standard of care status Stratification Study protocol subject survival survival rate survival rates Swab table the patient therapy time Total treated Treatment Trial underlying disease Viral load website worsening [DOI] 10.1186/s13063-020-04735-y PMC 바로가기 [Article Type] Letter
Association of Race and Ethnicity With Comorbidities and Survival Among Patients With COVID-19 at an Urban Medical Center in New YorkResearch Published on 2020-09-252022-10-29 Journal: JAMA Network Open [Category] COVID-19, SARS, [키워드] 95% CI acute respiratory syndrome age association black Black patient Care Case fatality rate category cause center Characteristics characterized cohort study Comorbidities Comorbidity coronavirus coronavirus disease COVID-19 Cox proportional hazard Critical death death rate demographic characteristics Diagnosis died Ethnicity examined exposure finding Frame group groups hazard ratio Hispanic Hispanic patient Importance interquartile range measure Mortality multivariable New York New York City objective outcome overall survival participant Patient patients with COVID-19 Point polymerase chain positive positive COVID-19 positive test result presenting proportion Quantitative race Racial Relevance reported Result reverse transcription risk Risk factors SARS-CoV-2 setting Sex survival tested the median treated univariable urban while white White patient White patients women [DOI] 10.1001/jamanetworkopen.2020.19795 PMC 바로가기 [Article Type] Research
Tocilizumab and steroid treatment in patients with COVID-19 pneumonia코로나19 폐렴 환자에서 토실리주맙과 스테로이드 치료Research Article Published on 2020-08-202022-08-13 Journal: PLoS ONE [Category] Biochemistry, COVID-19, MERS, SARS, [키워드] 95%CI adjusted age analyses anti-inflammatory treatment Comorbidities Comorbidity controls coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 pneumonia Cox regression analysis darunavir death defined determine difference early treatment Efficacy Endpoint endpoints Evidence failure group hazard hazard ratio Hospital admission Hydroxychloroquine immune response IMPROVE intravenously Intubated intubation IQR lead male median median age Methylprednisolone non-intubated patient non-intubated patients not intubated outcome overall survival PaO Patient patients with COVID-19 Pneumonia primary endpoint Propensity score Ratio Respiratory failure Result Ritonavir Severe COVID-19 pneumonia single-center study Standard of care steroid steroid treatment Steroids subcutaneously survival Tocilizumab treated patient Treatment treatment with tocilizumab with COVID-19 [DOI] 10.1371/journal.pone.0237831 PMC 바로가기 [Article Type] Research Article
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study중증 COVID-19에 대한 JAK1/2 억제제 룩소리티닙의 동정적 사용: 전향적 관찰 연구Clinical Trial Published on 2020-08-192022-08-13 Journal: Leukemia [Category] MERS, SARS, 바이오마커, 신약개발, 임상, 치료제, [키워드] 95% confidence interval activated adverse event age Anemia anti-inflammatory properties clinical Clinical improvement Comorbidities Comorbidity compassionate-use compassionate-use protocol contribute Controlled clinical trial controlled clinical trials COVID-19 cumulative incidence cytokine defined discharge home distress Efficacy exposure time FiO2 high-flow oxygen support improvement Infectious diseases Inflammatory cytokine inflammatory cytokine profile inflammatory reaction inhibitor JAK1 JAK1/JAK2 inhibitor JAK2 less lymphocyte Lymphocyte subset median age median dose intensity not affected observational study Ordinal Scale overall survival oxygen oxygen saturation PaO2 paO2/fiO2 PaO2/FiO2 ratio Patient patients with COVID-19 prospective cohort prospective observational study pulmonary disease Pulmonary function pulmonary infiltrate pulmonary infiltrates respiratory distress ruxolitinib Safe severe COVID-19 severe pulmonary disease Therapeutics thrombocytopenia urinary tract infections [DOI] 10.1038/s41375-020-01018-y PMC 바로가기 [Article Type] Clinical Trial
Perioperative antiviral therapy improves the prognosis of HBV DNA-negative patients with HBV-related hepatocellular carcinomaArticle Published on 2020-08-012023-06-13 Journal: Expert review of gastroenterology & hepatology [Category] B형 간염, [키워드] HBV DNA Hepatectomy hepatitis B Hepatocellular carcinoma overall survival Prognosis [DOI] 10.1080/17474124.2020.1784727
Liver Resection for Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: a Multicenter Propensity Matching Analysis with HBV-HCCComparative Study Published on 2020-02-012023-06-13 Journal: Journal of Gastrointestinal Surgery [Category] B형 간염, [키워드] Hepatectomy Hepatitis B virus Hepatocellular carcinoma Non-alcoholic fatty liver disease overall survival Recurrence-free survival. [DOI] 10.1007/s11605-018-04071-2 [Article Type] Comparative Study